Table 2.
Incidence of CVD, renal, and mortality outcomes by APOL1 renal-risk genotype in African American SPRINT participants
|
APOL1 G1+G2 = 2 |
APOL1 G1+G2 = 0/1 |
Recessive model |
Additive model |
|||||
|---|---|---|---|---|---|---|---|---|
| No. with events n = 360 |
% With events per yr (95% CI) |
No. with events n = 2208 |
% With events per yr (95% CI) |
HR (95% CI) | P value | HR (95% CI) | P value | |
| All participants | ||||||||
| CVD primary outcomea | 22 | 1.97 (1.30, 2.99) | 106 | 1.53 (1.26, 1.85) | 1.20 (0.76, 1.92) | 0.435 | 1.10 (0.86, 1.41) | 0.458 |
| MI | 6 | 0.53 (0.24, 1.18) | 39 | 0.56 (0.41, 0.76) | 1.02 (0.43, 2.45) | 0.961 | 1.12 (0.73, 1.72) | 0.607 |
| ACS not resulting in MI | 2 | 0.18 (0.04, 0.70) | 12 | 0.17 (0.10, 0.30) | 1.04 (0.23, 4.79) | 0.958 | 1.02 (0.47, 2.20) | 0.957 |
| Stroke | 7 | 0.62 (0.30, 1.30) | 23 | 0.33 (0.22, 0.49) | 1.66 (0.70, 3.92) | 0.251 | 1.26 (0.77, 2.08) | 0.359 |
| Heart failure | 7 | 0.62 (0.30, 1.30) | 39 | 0.55 (0.41, 0.76) | 0.98 (0.43, 2.23) | 0.970 | 0.83 (0.54, 1.28) | 0.403 |
| CVD death | 4 | 0.35 (0.13, 0.94) | 22 | 0.31 (0.20, 0.47) | 0.94 (0.32, 2.75) | 0.905 | 1.27 (0.74, 2.16) | 0.384 |
| Nonfatal MI | 6 | 0.53 (0.24, 1.18) | 38 | 0.54 (0.39, 0.74) | 1.07 (0.45, 2.57) | 0.879 | 1.12 (0.72, 1.72) | 0.618 |
| Nonfatal stroke | 7 | 0.62 (0.30, 1.30) | 22 | 0.31 (0.21, 0.48) | 1.76 (0.74, 4.18) | 0.202 | 1.26 (0.76, 2.09) | 0.379 |
| Nonfatal heart failure | 7 | 0.62 (0.30, 1.30) | 37 | 0.53 (0.38, 0.73) | 1.05 (0.46, 2.39) | 0.905 | 0.89 (0.58, 1.38) | 0.609 |
| All-cause mortality | 16 | 1.40 (0.86, 2.29) | 79 | 1.11 (0.89, 1.39) | 1.19 (0.69, 2.05) | 0.530 | 1.10 (0.82, 1.46) | 0.529 |
| Primary + all-cause mortality | 32 | 2.85 (2.02, 4.04) | 145 | 2.09 (1.77, 2.46) | 1.28 (0.87, 1.89) | 0.212 | 1.10 (0.89, 1.36) | 0.361 |
| eGFR< 60 ml/min/1.73 m2 | ||||||||
| Primary CKD outcomeb | 1 / 102 | 0.29 (0.04, 2.09) | 10 / 524 | 0.59 (0.32, 1.09) | 0.48 (0.03, 2.51) | 0.482 | 0.56 (0.19, 1.33) | 0.228 |
| Incident albuminuriac | 0 / 21 | — | 23 / 201 | 3.87 (2.57, 5.83) | — | — | 0.70 (0.35, 1.34) | 0.301 |
| eGFR ≥ 60 ml/min/1.73 m2 | ||||||||
| Secondary CKD outcomed | 13 / 257 | 1.66 (0.97, 2.86) | 53 / 1,678 | 0.99 (0.76, 1.29) | 1.64 (0.85, 2.93) | 0.114 | 1.06 (0.73, 1.50) | 0.766 |
| Incident albuminuriac | 10 / 128 | 2.73 (1.47, 5.07) | 61 / 961 | 2.08 (1.62, 2.67) | 1.32 (0.63, 2.50) | 0.417 | 1.41 (1.00, 1.99) | 0.051 |
ACS, acute coronary syndrome; CKD, chronic kidney disease; CI, confidence interval; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio; MI, myocardial infarction; SPRINT = Systolic Blood Pressure Intervention Trial.
HRs for CKD and albuminuria outcomes adjusted for age, sex, African admixture, and treatment group. HRs for CVD outcomes and all-cause mortality additionally adjusted for eGFR and log (urine albumin:creatinine ratio).
Includes nonfatal MI, ACS not resulting in MI, nonfatal stroke, nonfatal acute decompensated heart failure, and cardiovascular disease death.
Includes a 50% reduction in eGFR (measured twice ≥90 days apart), dialysis, or kidney transplantation.
Applies only to participants with urine albumin:creatinine ratio <10 mg/g at baseline, and required a doubling from < 10 mg/g to ≥ 10 mg/g (measured twice ≥90 days apart).
Includes a 30% reduction in eGFR (measured twice ≥90 days apart) to an eGFR < 60 ml/min/1.73 m2, dialysis, or kidney transplantation.